Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm

Michal Nordkin¹, Nashwa Fadaos², Ronit Leiba³, Nurit Sharon-Horesh¹, Ben Varon¹, Ofrat Beyar-Katz^{1

4}, Tsofia Levi¹, Netanel A Horowitz^{1

4}, Inna Tzoran^{1

4}, Noa Lavi^{1

4}, Tsila Zuckerman^{1

4}, Eldad J Dann^{1

4}, Shimrit Ringelstein-Harlev^{1

4}

Affiliations

¹ Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
² Department of Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
³ Department of Statistics, Rambam Health Care Campus, Haifa, Israel.
⁴ Ruth and Bruce Rappaport Faculty of Medicine Technion, Haifa, Israel.

Michal Nordkin et al. Br J Haematol. 2025 Sep.

. 2025 Sep;207(3):1104-1107.

doi: 10.1111/bjh.20261. Epub 2025 Jul 7.

¹ Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
² Department of Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
³ Department of Statistics, Rambam Health Care Campus, Haifa, Israel.
⁴ Ruth and Bruce Rappaport Faculty of Medicine Technion, Haifa, Israel.

No abstract available

Keywords: 2‐year maintenance; anti‐CD20 monoclonal antibodies; follicular lymphoma.

References

1. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, et al. Rituximab as first‐line and maintenance therapy for patients with indolent non‐Hodgkin's lymphoma. J Clin Oncol. 2002;20(20):4261–4267.
1. Bachy E, Seymour JF, Feugier P, Offner F, Lopez‐Guillermo A, Belada D, et al. Sustained progression‐free survival benefit of rituximab maintenance in patients with follicular lymphoma: long‐term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–2824.
1. Rummel M, Buske C, Hertenstein B, Lerchenmüller C, Koenigsmann M, Lange E, et al. Four versus two years of rituximab maintenance (R‐maintenance) following Bendamustine plus rituximab (B‐R): initial results of a prospective, randomized multicenter phase 3 study in first‐line follicular lymphoma (the StiL NHL7‐2008 MAINTAIN study). Blood. 2017;130:483.
1. Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, et al. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma: results of the phase III MabCute study. Haematologica. 2022;107(2):500–509.
1. Hong H, Choi SM, Jeon YW, Kim TY, Kim S, An TJ, et al. The outcome of SARS‐CoV‐2 infection in patients with lymphoma and the risk factors for the development of pneumonia. Infect Chemother. 2024;56(3):378–385.